Fifty years of experience with cortisone therapy in the study and treatment of rheumatoid arthritis

Annals of the New York Academy of Sciences

Volumn 966, Issue , 2002, Pages 28-38

  Neeck, Gunther ^a,b  

^a Rostock Clinic South   (Germany)

^b Division of Rheumatology and Clinical Immunology   (Germany)

Author keywords

Cortisone therapy; Rheumatoid arthritis

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTISONE; ETIDRONIC ACID; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RISEDRONIC ACID; STEROID; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

BONE INJURY; CARTILAGE; CELL PROLIFERATION; CONFERENCE PAPER; CROHN DISEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HISTORY OF MEDICINE; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IMMUNOSTIMULATION; OBSERVATION; PATHOPHYSIOLOGY; QUALITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; SIDE EFFECT; STEROID THERAPY;

EID: 0036300850     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2002.tb04199.x     Document Type: Conference Paper

References (66)

1. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis: Preliminary report
2. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions
3. The glucocorticoid receptor
4. The glucocorticoid hormone receptor
5. Transcriptional cross-talk, the second mode of steroid hormone receptor action
6. Glucocorticoid-induced apoptosis in lymphocytes
7. Molecular genetic dissection of glucocorticoid receptor function in vivo
8. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis: A report of the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases
9. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis: A report of the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases
10. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis: A second report of the joint committee of the Medical Research Council and Nuffield Foundation on clinical trials of cortisone, ACTH, and other therapeutic measures in chronic rheumatic diseases
11. Rheumatoid arthritis: The relevance of clinical knowledge to research activities
12. Low dose glucocorticoid therapy in rheumatoid arthritis (RA): Transitional or add-on therapy?
13. Corticosteroids in rheumatoid arthritis - Is a trial of their disease modifying potential feasible?
14. The effect of glucocorticoids on joint destruction in rheumatoid arthritis
15. The Arthritis and Rheumatism Council low-dose glucocorticoid study group: Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis
16. Low dose glucocorticoids in early RA inhibit radiological joint damage
17. Low-dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis
18. Effects of long-term glucocorticoid therapy in rheumatoid arthritis
19. Reforming the pyramid: A plan for treating rheumatoid arthritis in the 1990s
20. Rheumatology: Challenges for the millennium
21. Low-dose prednisone therapy
22. Preventing glucocorticoid-induced osteoporosis
23. Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones
24. Immunoendocrine communication via the hypothalamus-pituitary-adrenal axis in autoimmune diseases
25. The cytokine-HPA axis circuit contributes to prevent or moderate autoimmune processes
26. Effect of Newcastle Disease Virus administration to mice on the metabolism of cerebral monoamines, plasma corticosterone and lymphocyte proliferation
27. In the mouse, the activation of the hypothalamic-pituitary-adrenal axis by a lipopolysaccharide (endotoxin) is mediated through interleukin-1
28. Selective depletion of macrophages prevents pituitary-adrenal activation in response to subpyrogenic but not to pyrogenic doses of bacterial endotoxin in rats
29. Significance of increased secretion of glucocorticoids in mice and rats injected with bacterial endotoxin
30. Disturbed immune-endocrine communication in autoimmune disease. Lack of corticosterone response to immune signals in obese strain chickens with spontaneous autoimmune thyroiditis
31. Analysis of the immune-endocrine feedback loop in the avian system and its alteration in chicken with spontaneous autoimmune thyroiditis
32. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats
33. Cytokines mediate the protective stimulation of glucocorticoid output during autoimmunity: Involvement of IL-1
34. Hypothalamic-pituitary-adrenal-glucocorticoid axis in rheumatoid arthritis
35. Studies on adrenal cortical activity in patients with rheumatoid arthritis: The diurnal pattern and twenty-four hour levels of urinary total 17-hydroxycorticosteroids and 17-ketosteroids
36. Corticosteroids in rheumatoid arthritis: Studies on aldosterone, 17-hydroxycorticosteroid, and 17-ketosteroid response to corticotropin in male patients with rheumatoid arthritis
37. Low adrenal androgenic-anabolic steroids in women with rheumatoid arthritis (RA): Gas/liquid chromatographic studies in RA patients and matched normal control women indicating decreased 11-deoxy-17-ketosteroid excretion
38. Response to glucocorticoid treatment in rheumatoid arthritis: In vitro cell mediated immune assay predicts in vivo responses
39. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis
40. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis: Effect of glucocorticoids
41. Dysregulation of the hypothalamus-pituitary axis in rheumatoid arthritis
42. Hypothalamo-pituitary-adrenal axis and growth hormone axis in patients with rheumatoid arthritis
43. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: A controlled study using insulin hypoglycemia stress test and prolactin stimulation
44. Adrenal androgen and glucocorticoid dissociation in premenopausal rheumatoid arthritis: A significant correlate or precursor to onset?
45. Comparative study of symptoms and neuroendocrine-immune network mediator levels between rheumatoid arthritis patients and healthy subjects
46. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis
47. Expression analysis of the glucocorticoid receptor and the nuclear factor kappa B subunit p50 in lymphocytes from patients with rheumatoid arthritis
48. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedione, cortisol or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor
49. Adrenal secretion of cortisol in patients with rheumatoid arthritis
50. Correlation of IL-6 with the classical humoral disease activity parameters ESR and CRP and with serum cortisol, reflecting the activity of the HPA axis in active rheumatoid arthritis
51. Investigations of neopterin, soluble interleukin-2 receptor and cortisol in rheumatoid arthritis
52. Effects of glucocorticoids in rheumatoid arthritis: Diminished glucocorticoid receptors do not result in glucocorticoid resistance
53. Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic disease
54. Infliximab (chimeric antitumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
55. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
56. Role of CSB/p38/RK stress response kinase in LPS and cytokine signaling mechanisms
57. 1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
58. Novel homologues of CSBP/p38 MAP kinase: Activation, substrate specificity and sensitivity of inhibition by pyridinyl imidazoles
59. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism
60. Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen activated protein kinase, in rat adjuvant-induced arthritis
61. Immunomodulation by thalidomide and thalidomide analogues
62. Thalidomide: Current and potential clinical applications
63. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
64. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-α) translation: Glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK
65. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis